PortfoliosLab logo

Cerevel Therapeutics Holdings, Inc. (CERE)

Equity · Currency in USD · Last updated Aug 6, 2022

Company Info

ISINUS15678U1280
CUSIP15678U128
SectorHealthcare
IndustryBiotechnology

Trading Data

Previous Close$33.47
Year Range$20.62 - $44.64
EMA (50)$27.68
EMA (200)$29.06
Average Volume$514.90K
Market Capitalization$4.97B

CEREShare Price Chart


Chart placeholderClick Calculate to get results

CEREPerformance

The chart shows the growth of $10,000 invested in Cerevel Therapeutics Holdings, Inc. in Jul 2020 and compares it to the S&P 500 index or another benchmark. It would be worth nearly $28,126 for a total return of roughly 181.26%. All prices are adjusted for splits and dividends.


-30.00%-20.00%-10.00%0.00%10.00%20.00%MarchAprilMayJuneJulyAugust
10.24%
-9.64%
CERE (Cerevel Therapeutics Holdings, Inc.)
Benchmark (^GSPC)

CEREReturns in periods

Returns over 1 year are annualized

PeriodReturnBenchmark
1M9.27%8.19%
6M27.70%-7.42%
YTD3.24%-13.03%
1Y28.34%-5.85%
5Y67.03%12.89%
10Y67.03%12.89%

CEREMonthly Returns Heatmap


JanFebMarAprMayJunJulAugSepOctNovDec
2022-19.68%1.65%32.26%-16.37%-10.76%1.19%-0.57%27.31%
2021-22.38%17.79%-9.43%5.97%-9.83%95.27%-3.83%28.49%-6.82%37.80%-23.27%3.94%
2020-5.88%-5.36%-1.42%-1.44%37.09%17.42%

CERESharpe Ratio Chart

The Sharpe ratio shows whether the portfolio's excess returns are due to smart investment decisions or a result of taking a higher risk. The higher a portfolio's Sharpe ratio, the better its risk-adjusted performance.

The current Cerevel Therapeutics Holdings, Inc. Sharpe ratio is 0.34. A Sharpe ratio between 0 and 1.0 is considered sub-optimal.

The chart below displays rolling 12-month Sharpe Ratio.


-0.500.000.501.00MarchAprilMayJuneJulyAugust
0.34
-0.31
CERE (Cerevel Therapeutics Holdings, Inc.)
Benchmark (^GSPC)

CEREDividend History


Cerevel Therapeutics Holdings, Inc. doesn't pay dividends

CEREDrawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way.


-50.00%-40.00%-30.00%-20.00%-10.00%0.00%SeptemberOctoberNovemberDecember2022FebruaryMarchAprilMayJuneJulyAugust
-25.02%
-13.58%
CERE (Cerevel Therapeutics Holdings, Inc.)
Benchmark (^GSPC)

CEREWorst Drawdowns

The table below shows the maximum drawdowns of the Cerevel Therapeutics Holdings, Inc.. A maximum drawdown is an indicator of risk. It shows a reduction in portfolio value from its maximum due to a series of losing trades.

The maximum drawdown since January 2010 for the Cerevel Therapeutics Holdings, Inc. is 53.81%, recorded on May 11, 2022. The portfolio has not recovered from it yet.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-53.81%Nov 5, 2021129May 11, 2022
-32.29%Dec 18, 202069Mar 30, 202163Jun 29, 2021132
-28.39%Jun 30, 202112Jul 16, 202129Aug 26, 202141
-24.07%Sep 22, 20217Sep 30, 202116Oct 22, 202123
-17.48%Jul 31, 202069Nov 5, 20206Nov 13, 202075
-6.57%Dec 8, 20201Dec 8, 20207Dec 17, 20208
-5.82%Sep 13, 20211Sep 13, 20214Sep 17, 20215
-4.15%Nov 24, 20201Nov 24, 20202Nov 27, 20203
-3.59%Sep 8, 20211Sep 8, 20212Sep 10, 20213
-3.05%Oct 25, 20212Oct 26, 20212Oct 28, 20214

CEREVolatility Chart

Current Cerevel Therapeutics Holdings, Inc. volatility is 78.63%. The chart below shows the rolling 10-day volatility. Volatility is a statistical measure showing how big price swings are in either direction. The higher asset volatility, the riskier it is, because the price movements are less predictable.


20.00%40.00%60.00%80.00%100.00%120.00%140.00%MarchAprilMayJuneJulyAugust
78.63%
19.67%
CERE (Cerevel Therapeutics Holdings, Inc.)
Benchmark (^GSPC)